Float Short %

2.08

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.07

EPS Last/This Y

4.76

EPS This/Next Y

-0.31

Price

2.86

Target Price

4.8

Analyst Recom

Performance Q

-0.7

Relative Volume

1.13

Beta

-3.3

Ticker: IBIO

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	IBIO	2.48	N/A	N/A	0
2024-12-20	IBIO	2.49	N/A	N/A	0
2024-12-23	IBIO	2.4	N/A	N/A	0
2024-12-24	IBIO	2.4153	N/A	N/A	0
2024-12-26	IBIO	2.45	N/A	N/A	0
2024-12-27	IBIO	2.43	N/A	N/A	0
2024-12-30	IBIO	2.4	N/A	N/A	0
2024-12-31	IBIO	2.4669	N/A	N/A	0
2025-01-02	IBIO	2.365	N/A	N/A	0
2025-01-03	IBIO	2.45	N/A	N/A	0
2025-01-06	IBIO	2.43	N/A	N/A	0
2025-01-07	IBIO	2.68	N/A	N/A	0
2025-01-08	IBIO	2.7123	N/A	N/A	0
2025-01-09	IBIO	2.72	N/A	N/A	0
2025-01-10	IBIO	2.6	N/A	N/A	0
2025-01-13	IBIO	2.445	N/A	N/A	0
2025-01-14	IBIO	2.65	N/A	N/A	0
2025-01-15	IBIO	2.83	N/A	N/A	0
2025-01-16	IBIO	2.76	N/A	N/A	0
2025-01-17	IBIO	2.81	N/A	N/A	0
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	IBIO	2.38	-	-	-1.74
2024-12-20	IBIO	2.51	-	-	-1.74
2024-12-23	IBIO	2.36	-	-	-1.74
2024-12-24	IBIO	2.42	-	-	-1.74
2024-12-26	IBIO	2.41	-	-	-1.74
2024-12-27	IBIO	2.46	-	-	-1.74
2024-12-30	IBIO	2.40	-	-	-1.74
2024-12-31	IBIO	2.38	-	-	-1.74
2025-01-02	IBIO	2.35	-	-	-1.74
2025-01-03	IBIO	2.45	-	-	-1.74
2025-01-06	IBIO	2.48	-	-	-1.74
2025-01-07	IBIO	2.70	-	-	-1.74
2025-01-08	IBIO	2.72	-	-	-1.74
2025-01-09	IBIO	2.72	-	-	-1.74
2025-01-10	IBIO	2.55	-	-	-1.74
2025-01-13	IBIO	2.43	-	-	-1.74
2025-01-14	IBIO	2.67	-	-	-1.74
2025-01-15	IBIO	2.85	-	-	-1.74
2025-01-16	IBIO	2.77	-	-	-1.74
2025-01-17	IBIO	2.86	-	-	-1.74
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	IBIO	0.00	6.65	2.22
2024-12-20	IBIO	0.00	6.65	2.22
2024-12-23	IBIO	0.00	6.65	2.22
2024-12-24	IBIO	0.00	6.65	2.22
2024-12-26	IBIO	0.00	6.65	2.80
2024-12-27	IBIO	0.00	6.65	2.80
2024-12-30	IBIO	0.00	6.65	2.80
2024-12-31	IBIO	0.00	6.65	2.80
2025-01-02	IBIO	0.00	6.65	2.80
2025-01-03	IBIO	0.00	6.65	2.80
2025-01-06	IBIO	0.00	6.65	2.80
2025-01-07	IBIO	0.00	6.65	2.80
2025-01-08	IBIO	0.00	6.65	2.80
2025-01-09	IBIO	0.00	6.65	2.80
2025-01-10	IBIO	0.00	6.65	2.80
2025-01-13	IBIO	0.00	7.69	2.08
2025-01-14	IBIO	0	7.69	2.08
2025-01-15	IBIO	0	7.69	2.08
2025-01-16	IBIO	0	7.69	2.08
2025-01-17	IBIO	0	7.69	2.08
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.46

Avg. EPS Est. Current Quarter

-0.45

Avg. EPS Est. Next Quarter

-0.39

Insider Transactions

Institutional Transactions

7.69

Beta

-3.3

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.9

Max Drawdown 5-Year %

-100

Target Price

4.8

P/E

Forward P/E

PEG

P/S

152.29

P/B

1.38

P/Free Cash Flow

EPS

-6.64

Average EPS Est. Cur. Y

-1.74

EPS Next Y. (Est.)

-2.05

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-13228.57

Relative Volume

1.13

Return on Equity vs Sector %

-149.5

Return on Equity vs Industry %

-136.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

iBio, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 16

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

stock quote shares IBIO – iBio Inc Stock Price stock today

news today IBIO – iBio Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch IBIO – iBio Inc yahoo finance google finance

stock history IBIO – iBio Inc invest stock market

stock prices IBIO premarket after hours

ticker IBIO fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: IBIO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y